Merck's Keytruda helps lung cancer patients live longer in trial

(Reuters) - Merck& Co's blockbuster drug Keytruda helped previously untreated lung cancer patients live longer in a late-stage trial, potentially cementing its position as the dominant player in the lucrative lung cancer market.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news